OptiForm® Solution Suite Accelerates Bioavailability Enhancement For Early Phase Molecule
Summary: A biotech company developed an extremely poorly soluble new molecule in pre-clinical phase. Catalent provided a structured approach with its new offering OptiForm® Solution Suite, to help select the most suitable formulation technology to enhance the molecule’s bioavailability. In just 12 weeks, experts at Catalent conducted a thorough assessment of the molecule’s characteristics, evaluated multiple bioavailability enhancement technologies in parallel, and finally delivered the optimal formulation. This integrated service efficiently and rapidly helped the molecule progressing to animal PK studies, and the enhanced bioavailability enabled the single ascending dose studies in phase I.